Docetaxel and Carboplatin for Ovarian Cancer
Author Information
Author(s): Vasey P A, Atkinson R, Coleman R, Crawford M, Cruickshank M, Eggleton P, Fleming D, Graham J, Parkin D, Paul J, Reed N S, Kaye S B
Primary Institution: CRC Department of Medical Oncology, Beatson Oncology Centre, Western Infirmary, Glasgow
Hypothesis
Can a combination of carboplatin and docetaxel be an effective first-line chemotherapy for epithelial ovarian cancer?
Conclusion
The study found that the carboplatin-docetaxel combination is effective, with a 66% overall response rate.
Supporting Evidence
- 110 patients (79%) completed 6 cycles of chemotherapy.
- 104 patients (75%) experienced grade IV neutropenia.
- The overall response rate for the study was 66%.
Takeaway
Doctors tested a new medicine for women with a type of cancer, and it worked well for many of them.
Methodology
A prospective, non-randomized, multicentre, open, dose-finding study was conducted.
Limitations
The study was non-randomized and had a relatively small sample size.
Participant Demographics
Median age of participants was 56 years, with ages ranging from 28 to 85.
Statistical Information
Confidence Interval
95% CI 13.3–19.1
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website